Partner

Articles & Insights / Stability Science

How to Design a Stability Study That Supports a Defensible Shelf Life

A shelf life is a conclusion drawn from product behaviour in a defined pack under defined conditions. A useful stability programme therefore begins with the intended product, market and use pattern, then selects experiments capable of detecting the changes that matter.

Stabicon Life Sciences4 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Begin with the product and the decision
  • Select attributes that can change
  • Make batches and packaging representative

Begin with the product and the decision

Before placing samples in a chamber, define the dosage form, strengths, formulation, intended storage statement, container closure system and proposed shelf life. Identify whether the decision concerns initial registration, a formulation comparison, a packaging change or an extension of an existing shelf life. These decisions require different evidence packages. A screening experiment can rank prototypes without providing the representative batch evidence needed for a commercial shelf-life claim.

For medicines, identify the guidance adopted by the target authority and the relevant submission pathway. For nutraceuticals and natural products, establish the applicable food or supplement requirements separately. Pharmaceutical stability principles can inform study design, but their use does not automatically make a food product subject to pharmaceutical registration requirements. The consolidated ICH Q1 document was listed by FDA as draft guidance when checked for this collection; draft recommendations should not be described as implemented requirements. R01R03R24

Select attributes that can change

An assay-only programme can miss a failing product. A tablet may retain its active content while its dissolution slows. A liquid may remain chemically acceptable while precipitation affects dose delivery. A botanical product may meet one marker specification while its broader fingerprint changes. Select physical, chemical, microbiological and functional measurements according to plausible failure mechanisms.

For a moisture-sensitive chewable, a useful development panel might include active content, relevant degradation products, water content, texture or breaking force, appearance and microbiological quality where appropriate. Sampling should capture the product actually supplied to the user. A composite assay cannot establish unit-to-unit uniformity, and testing a liquid after ideal laboratory mixing may conceal difficulties with the labelled shaking instruction.

Make batches and packaging representative

Use batches that represent the proposed composition, process and material controls. Record differences between development and intended commercial manufacture so their significance can be assessed. Select the marketed packaging early enough to generate relevant evidence. Unprotected samples provide useful mechanistic information but cannot substitute for stability data in the proposed commercial pack.

Different fill counts, headspaces or closure systems can change exposure. Bracketing and matrixing reduce testing only where the scientific justification and applicable guidance support them. An assumption that the largest bottle is always the worst case is unreliable because headspace, closure performance and frequency of opening may interact. R01R02

Use accelerated studies for the questions they can answer

Elevated temperature and humidity help identify vulnerabilities and compare options. They do not create a universal conversion between a few months in a chamber and several years on a shelf. A formulation can change its physical state or degradation pathway under severe conditions. In that situation, a simple acceleration model may no longer describe real storage.

Select long-term and accelerated conditions for the product, pack and intended markets. Add photostability, temperature cycling, transport or in-use studies when their questions are relevant. For a multidose bottle, repeated opening may create an exposure that a continuously sealed sample never experiences. These studies complement the core programme rather than replace it.

Interpret trends before the limit is crossed

Review individual batches, variability and the relationship between attributes. A rising impurity accompanied by a falling assay suggests a different investigation from an isolated analytical shift. Where regression is appropriate, document model assumptions and uncertainty. Do not extrapolate a shelf life solely from the point where an average line meets a limit; the regulatory evaluation and relevant confidence bounds also matter. R02

The illustration illustrates why two batches with acceptable results today may have different remaining margins. The lines are invented for explanation and establish no shelf life. In practice, the decision must account for every relevant attribute, including those that cannot be represented by a simple linear model.

Explore the scienceAcceptable results can have different trend margins
Assay (% of label claim)8891.59598.51020369121824Illustrative lower criterion Hypothetical batch A: 0, 100Hypothetical batch A: 3, 99.7Hypothetical batch A: 6, 99.2Hypothetical batch A: 9, 98.8Hypothetical batch A: 12, 98.1Hypothetical batch A: 18, 97.2Hypothetical batch A: 24, 96 Hypothetical batch B: 0, 100Hypothetical batch B: 3, 99.1Hypothetical batch B: 6, 98.4Hypothetical batch B: 9, 97.5Hypothetical batch B: 12, 96.5Hypothetical batch B: 18, 94.8Hypothetical batch B: 24, 93.1Storage time (months)

Invented teaching data; not Stabicon experimental results. No shelf life or confidence bounds are calculated.

Two invented assay trends remain above an illustrative lower criterion while their margins differ. No statistical bounds are plotted; this is not a shelf-life calculation.

A practical development example

Consider a vitamin tablet that remains within assay limits but softens in a bottle during development. Compare the original pack with an alternative closure or desiccant configuration while tracking moisture and physical performance. If the alternative reduces moisture uptake without introducing another problem, it becomes a candidate for confirmation in a representative programme. The experiment supports a packaging decision; it does not, by itself, justify a new expiry date.

Stabicon can help connect protocol design, controlled storage and analytical evaluation so that stability findings inform formulation and packaging decisions as well as shelf-life assessment.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R01
    ICH Q1A R2 Stability Testing of New Drug Substances and Products

    Final guideline, 2003. Pharmaceutical scope; apply target-authority requirements.

  2. R02
    ICH Q1E Evaluation for Stability Data

    Final guideline, 2003. Evaluation and justified extrapolation of stability data.

  3. R03
    ICH Q1D Bracketing and Matrixing Designs for Stability Testing

    Final guideline, 2002. Reduced designs require scientific justification.

  4. R24
    FDA Q1 Stability Testing of Drug Substances and Drug Products

    Draft guidance, June 2025, as listed when checked. Not for implementation.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin